

February 15 2018

18-02511-E

US Securities & Exchange Commission  
Office of FOIA and Privacy Act Operations  
100 F Street, NE Mail Stop 5100  
Washington, DC 20549-5100



Dear FOIA Office:

Under the Freedom of Information Act (FOIA), please send a copy of the following:

**A copy of: Exhibit 10.2 to the form 8-K filed by VIA Pharmaceuticals on December 23, 2008**

In the event confidential treatment has not expired provide the specific date for which

confidential treatment is still in effect. I do not need a copy of the order. We authorize up to

\$61.00 in processing fees. Thank You,

**Paul D'Souza**  
Editor - Deals

**Clarivate Analytics** Friars House, 160 Blackfriars Road London, UK SE1 8EZ  
Phone: +44-2074334789  
[paul.dsouza@clarivate.com](mailto:paul.dsouza@clarivate.com)



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
STATION PLACE  
100 F STREET, NE  
WASHINGTON, DC 20549-2465

Office of FOIA Services

March 7, 2018

Mr. Paul D'Souza  
Clarivate Analytics  
160 Blackfriars Road  
London UK SE18EZ

RE: Freedom of Information Act (FOIA), 5 U.S.C. § 552  
Request No. 18-02511-E

Dear Mr. D'Souza:

This letter is in response to your request, dated and received in this office on February 15, 2018, for Exhibit 10.2 to the Form 8-K filed by VIA Pharmaceuticals on December 23, 2008.

The Commission granted confidential treatment to Exhibit 10.2 to the Form 8-K under Rule 24b-2 of the Securities Exchange Act of 1934 through December 23, 2018. Since confidential treatment has not expired, we are providing the expiration date from the relevant CT order as requested.

If you have any questions, please contact me at [morrowa@sec.gov](mailto:morrowa@sec.gov) or (202) 551-8376. You may also contact me at [foiapa@sec.gov](mailto:foiapa@sec.gov) or (202) 551-7900. You also have the right to seek assistance from a FOIA Public Liaison, Jeffery Ovall at (202) 551-7900.

Sincerely,

A handwritten signature in black ink that reads "Alysia Morrow".

Alysia Morrow  
FOIA Research Specialist